IP Library Granted Patent US 9,624,189
Granted Patent B2
US 9,624,189 · App. 13/796,248 · Granted Apr 18, 2017

Fluorinated benzofuran derivatives

Inventors: Mark E. Duggan (Wellesley, MA); Takeru Furuya (Cambridge, MA); D. Scott Edwards (Bedford, MA)
Assignee: SciFluor Life Sciences, Inc.
C07D307/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,624,189
App. No.
13/796,248
Granted
Apr 18, 2017
Kind
B2
Abstract

The invention relates to fluorinated compounds and their use in the field of pathological syndromes of the cardiovascular system. Novel fluorinated benzofuran derivatives of amiodarone and pharmaceutically acceptable salts or solvates thereof and their use for the treatment of arrhythmias are described.

Claims (26)

1. A compound of formula II:

or a pharmaceutically acceptable salt or solvate thereof, wherein X 2 is CF 3 and X 3 is selected from hydrogen, I, F, CF 3 , CHF 2 , CH 2 F, OCF 3 , OCHF 2 , and OCH 2 F.

2. The compound of claim 1 , wherein X 3 is selected from hydrogen, I, F, CF 3 , CHF 2 , and CH 2 F.

3. The compound of claim 1 , wherein X 3 is selected from hydrogen, I, and CF 3 .

4. A compound of formula II:

or a pharmaceutically acceptable salt or solvate thereof, wherein X 3 is hydrogen and X 2 is selected from F, CF 3 , CHF 2 , CH 2 F, OCF 3 , OCHF 2 , and OCH 2 F.

5. The compound of claim 4 , wherein X 2 is selected from F, CF 3 , CHF 2 , and CH 2 F.

6. The compound of claim 1 of formula VII:

or a pharmaceutically acceptable salt thereof.

7. A compound selected from

Compound #

1

2

3

11

or a pharmaceutically acceptable salt or solvate thereof.

8. A pharmaceutical composition comprising at least one compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof and one or more pharmaceutically acceptable carrier or excipient.

9. A compound of formula I:

or a pharmaceutically acceptable salt or solvate thereof, wherein X 1 , X 2 , X 3 , and X 4 are each independently selected from hydrogen, I, F, CF 3 , CHF 2 , CH 2 F, OCF 3 , OCHF 2 , and OCH 2 F, provided that at least one of X 1 , X 2 , X 3 , and X 4 is F or a group of atoms containing at least one fluorine atom; and wherein at least one hydrogen in the compound is substituted with a deuterium.

10. A deuterium labeled The compound of claim 9 that is

11. The compound of claim 7 , wherein the compound is

12. The compound of claim 7 , wherein the compound is

13. The compound of claim 7 , wherein the compound is

14. The compound of claim 7 , wherein the compound is

15. A pharmaceutical composition comprising at least one compound of claim 4 or a pharmaceutically acceptable salt or solvate thereof and one or more pharmaceutically acceptable carrier or excipient.

16. A pharmaceutical composition comprising at least one compound of claim 7 or a pharmaceutically acceptable salt or solvate thereof and one or more pharmaceutically acceptable carrier or excipient.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2026
From: OCUTERRA THERAPEUTICS, INC. (FORMERLY KNOWN AS SCIFLUOR LIFE SCIENCES, INC.)
To: FELIQS CORPORATION
Reel/Frame 073443/0692 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2015
From: SCIFLUOR LIFE SCIENCES, LLC
To: SCIFLUOR LIFE SCIENCES, INC.
Reel/Frame 035960/0496 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2013
From: DUGGAN, MARK E.; FURUYA, TAKERU; EDWARDS, D. SCOTT
To: SCIFLUOR LIFE SCIENCES, LLC
Reel/Frame 030617/0007 →
Continuity (3)
Provisional Application 61625359 · Apr 17, 2012
Provisional Application 61698994 · Sep 10, 2012
Related Publication 20130274325A1 · Oct 17, 2013